Pasithea Therapeutics (NASDAQ:KTTA) Posts Earnings Results, Beats Expectations By $0.33 EPS

Posted by Brenda Bartman on May 17th, 2026

Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) announced its earnings results on Friday. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.33, FiscalAI reports.

Pasithea Therapeutics Stock Down 1.8%

NASDAQ KTTA traded down $0.01 during mid-day trading on Friday, hitting $0.78. The stock had a trading volume of 549,445 shares, compared to its average volume of 404,809. Pasithea Therapeutics has a 52-week low of $0.28 and a 52-week high of $2.06. The company has a market cap of $19.46 million, a price-to-earnings ratio of -0.38 and a beta of 0.22. The company has a 50 day simple moving average of $0.77 and a 200 day simple moving average of $0.85.

Hedge Funds Weigh In On Pasithea Therapeutics

Several hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC increased its stake in Pasithea Therapeutics by 43.7% in the 3rd quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock valued at $48,000 after purchasing an additional 20,483 shares in the last quarter. Geode Capital Management LLC increased its stake in Pasithea Therapeutics by 113.9% in the 4th quarter. Geode Capital Management LLC now owns 54,495 shares of the company’s stock valued at $70,000 after purchasing an additional 29,020 shares in the last quarter. AdvisorShares Investments LLC increased its stake in Pasithea Therapeutics by 10.8% in the 1st quarter. AdvisorShares Investments LLC now owns 337,508 shares of the company’s stock valued at $250,000 after purchasing an additional 32,787 shares in the last quarter. Jane Street Group LLC increased its position in Pasithea Therapeutics by 137.0% during the fourth quarter. Jane Street Group LLC now owns 59,372 shares of the company’s stock worth $77,000 after buying an additional 34,319 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in Pasithea Therapeutics during the third quarter worth $26,000. 23.92% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

KTTA has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pasithea Therapeutics in a research report on Friday, March 27th. Zacks Research downgraded Pasithea Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 2nd. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of Pasithea Therapeutics in a research note on Monday, April 20th. Finally, Wall Street Zen raised Pasithea Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, January 18th. One equities research analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $3.00.

Check Out Our Latest Stock Analysis on Pasithea Therapeutics

About Pasithea Therapeutics

(Get Free Report)

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.